All In Biotech

Drug Trial Radar · NCT04411030

A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

A Two Cohort, Open-Label, Fixed Sequence Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam

Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

May 20, 2020

Primary completion

Aug 23, 2020

Study completion Aug 29, 2020

Sponsor

Lead sponsor
Astex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

In Part 1, the primary objective is to investigate the effect of multiple doses of itraconazole, an inhibitor of CYP3A4, on the pharmacokinetic (PK) profile of a single dose of ASTX660. In Part 2, the primary objective is to investigate the effect of a single dose of ASTX660 on the pharmacokinetics of the CYP3A4 substrate midazolam and its metabolite, 1-hydroxy midazolam. Safety and tolerability of a single dose of ASTX660 in the absence and presence of multiple doses of the CYP3A4 inhibitor itraconazole and in the presence of a single dose of the CYP3A4 substrate midazolam will also be evaluated.

Conditions

  • Healthy Volunteer

Interventions

  • ASTX660Drug

    Form: capsule; Route of administration: oral

  • MidazolamDrug

    Form: syrup; Route of administration: oral

  • ItraconazoleDrug

    Form: capsule; Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameter of ASTX660: CmaxTime frame: From predose up to Day 14
  2. Pharmacokinetic parameter of ASTX660: AUC0-tTime frame: From predose up to Day 14
  3. Pharmacokinetic parameter of ASTX660: AUC0-24Time frame: From predose up to Day 14
  4. Pharmacokinetic parameter of ASTX660: AUC0-infTime frame: From predose up to Day 14
  5. Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: CmaxTime frame: From predose up to Day 9
  6. Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-tTime frame: From predose up to Day 9
  7. Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-24Time frame: From predose up to Day 9
  8. Pharmacokinetic parameter of midazolam and 1-hydroxyl midazolam: AUC0-infTime frame: From predose up to Day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS Bio-kinetic

    Springfield, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.